ClinicalTrials.gg
CompletedNCT04171011Updated Oct 29, 2020

Nerve Stimulation During Esophagectomy

An interventional study of Stimulator device in Inflammatory Response, sponsored by Galvani Bioelectronics. Completed at 1 site in Netherlands. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2020-10-29.

Sponsored by Galvani Bioelectronics · Not applicable, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

Esophagectomy is the cornerstone for treatment of esophageal cancer. However, it is associated with substantial morbidity and mortality. Studies suggest that systemic inflammation after surgery has a negative impact on surgical outcomes. Attenuation of an excessive inflammatory response within the perioperative period for high-risk surgical procedures may reduce morbidity and mortality. The inflammatory response may be important in the development of these complications and reduction of inflammatory cytokine may be associated with an improved outcome.

The current study will evaluate the feasibility and safety of neuromodulation during minimally invasive surgery for esophageal cancer (esophagectomy) to assess impact on the inflammatory response. During the esophagectomy, a stimulation lead will be placed on the exposed nerves, and energy applied to the lead to test whether the nerves can be activated. The study will also measure potential physiological responses to nerve activation.

Read the detailed description

Active dampening of the inflammatory response may be an important therapeutic target to decrease complications and improve recovery following esophagectomy. The current study is intended to evaluate the feasibility and safety of stimulating the exposed nerves in esophagectomy patients.

During minimally invasive esophagectomy, a neurovascular bundle (NVB) is exposed or partially exposed as part of the obligatory lymph node dissection. At the point in the esophagectomy when the NVB is being isolated, a lead will be applied laparoscopically to the NVB and connected to an external pulse generator. An ultrasound transducer will be introduced to the abdomen and placed on the NVB to visualize splenic arterial blood flow. The NVB will be stimulated while physiologic responses are observed. Blood samples will be taken before, and at certain pre-defined time points after, stimulation and recovery. The lead and ultrasound transducer will be removed after completion of stimulation, and the esophagectomy surgery will continue. Surgeon experience applying and removing the cuff electrode will be documented, in addition to the responses to NVB stimulation. Post-operative safety will be followed through 7-days (or day of discharge if earlier).

02

Conditions studied

  • Inflammatory Response
03

In context

Lead sponsor

Galvani Bioelectronics is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female of non- or male
  • Undergoing minimally invasive esophagectomy
  • Confirmed presence of splenic NVB loop via imaging prior to surgery
  • Age equal or above 21 years at the screening visit
  • Capable of giving signed (IC)
  • Normal blood pressure, or hypertensive managed with medication such that they are deemed fit for surgery

Exclusion criteria

Exclusion Criteria:

  • Previous splenectomy
  • Existing implantable device
  • Active pancreatitis or history of severe pancreatitis with complications, hepatic or splenic disease
  • Use of oral 4 weeks prior to inclusion
  • Current use agents or biologicals. Previous use of biologicals is allowed, if a of 2 months is applied
  • Use of anticoagulants within 1 week of surgery
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Nerve Stimulation

    Participants will undergo brief NVB stimulation during the esophagectomy procedure.

    Device: Stimulator device

Interventions

  • DeviceStimulator device

    The stimulator device will be used to electrically stimulate the NVB

06

What researchers measure

Primary outcomes

  1. Feasibility applying and removing the stimulation lead: Proportion of participants in whom the lead was successfully applied and removed

    Proportion of participants in whom the lead was successfully applied and removed

    Time frame: 1 day

  2. Safety of placement, stimulation and removal of the lead: Incidence of adverse events

    Incidence of adverse events

    Time frame: 7 days

Secondary outcomes

  1. Peak Systolic Velocity (PSV) blood flow change measured by doppler ultrasound

    Time frame: Before stimulation and during stimulation

  2. End Diastolic Velocity (EDV) blood flow change measured by doppler ultrasound

    Time frame: Before stimulation and during stimulation

  3. Velocity Time Integral (VTI) blood flow change measured by doppler ultrasound

    Time frame: Before stimulation and during stimulation

Other outcomes

  1. Heart Rate (HR) change

    Time frame: Before stimulation and during stimulation

  2. Systolic Blood Pressure (SBP) change

    Time frame: Before stimulation and during stimulation

  3. Diastolic Blood Pressure (DBP) change

    Time frame: Before stimulation and during stimulation

  4. Mean Arterial Blood Pressure (MAP) change

    Time frame: Before stimulation and during stimulation

  5. Hematology (white blood cell (WBC) counts)

    Time frame: Before stimulation to Day 1 post stimulation

  6. Cytokine IL-6

    Time frame: Before stimulation to Day 1 post stimulation

  7. Cytokine IL-8

    Time frame: Before stimulation to Day 1 post stimulation

  8. Cytokine IL-10

    Time frame: Before stimulation to Day 1 post stimulation

  9. Cytokine TNF

    Time frame: Before stimulation to Day 1 post stimulation

  10. C-Reactive Protein level

    Time frame: At days 2 and 3 post stimulation

07

Study locations

1 site
  • Catharina Ziekenhuis
    Eindhoven, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Oct 2020, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2019
First posted
Nov 20, 2019
StartActual
Nov 28, 2019
Primary completionActual
Oct 6, 2020
CompletionActual
Oct 6, 2020
Last update
Oct 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04171011
Lead sponsor
Galvani Bioelectronics
Collaborators
NAMSA
Responsible party
Sponsor
First posted
Nov 20, 2019
Start date
Nov 28, 2019
Primary completion
Oct 6, 2020
Completion
Oct 6, 2020
Last update
Oct 29, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion